Cellectar Biosciences, Inc.
CLRB
$2.36
-$0.15-5.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.05% | 8.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.82% | 17.32% | |||
| Operating Income | -1.82% | -17.32% | |||
| Income Before Tax | -6.77% | -19.16% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.77% | -19.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.77% | -19.16% | |||
| EBIT | -1.82% | -17.32% | |||
| EBITDA | -1.76% | -17.56% | |||
| EPS Basic | -3.46% | 8.30% | |||
| Normalized Basic EPS | -3.46% | 8.30% | |||
| EPS Diluted | -3.46% | 8.60% | |||
| Normalized Diluted EPS | -3.46% | 8.30% | |||
| Average Basic Shares Outstanding | 3.20% | 29.94% | |||
| Average Diluted Shares Outstanding | 3.20% | 29.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||